About this episode
In 2005, Vamsi started his own company focused on data compliance for the pharmaceutical industry. His company provided technology to support clinical trials to the FDA. "I like to build companies, but I also like change. [After five years], I thought about selling the company and rolling it up into a publicly listed company." He sold it in 2010 and moved to India to pursue new opportunities. While the sale was smooth, there were numerous post-sale challenges. "They basically ran down the company within 18 months."
0:00 – 4:03 Vamsi's background at Deloitte, Pfizer, Merrill Lynch
4:04 – 6:27 Acquiring Clinovo (how found and why chose over others)
6:28 – 9:24 Due diligence process as a buyer
9:25 – 11:24 Issues that came up during diligence process
11:25 – 13:39 Working with the investment banker
13:40 – 14:19 Interaction with seller prior to closing
14:20 – 19:19 Challenges with integration
19:20 – 21:55 Lessons learned and post-closing challenges
21:56 – 23:05 Lessons from the sell side
23:06 – 23:38 What's on the horizon
M&A Science by Kison Patel ([email protected])
DealRoom: Data Science and AI for M&A (www.dealroom.net)
Get every episode summarized
Each time M&A Science publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from M&A Science
Cultural Fit Over EBITDA: How Salas O'Brien Built a 30-Merger Program Without a...
M&A Science
Cross-Border M&A: How to Do Deals in Italy with Mauro Sambati and Donato Romano
M&A Science
Four Questions That Defined a $1 Billion Deal with Robert Lovegrove
M&A Science
Stop Falling in Love with the Deal: Guardrails for High-Volume Acquisitions with...
M&A Science